Notice of Results

EKF Diagnostics Holdings plc (AIM: EKF) will announce preliminary results for the year ended 31 December 2015 on Tuesday 5 April 2016.

Investor presentation

A briefing for all investors will take place on Tuesday 5 April 2016 at Panmure’s office, One New change, EC4M 9AF from 5pm for a 5.15pm start, and will be followed by drinks.

If you would like to register for the investor presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com

EKF Diagnostics Holdings plc Ron Zwanziger, Non-Executive Chairman Julian Baines, CEO	00 44 29 2071 0570 00 1 339 221 6282 00 44 7788 420 859
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Diagnostics is previewing the new connectivity solution for A1c POC analyzers at Medica 2016

EKF Diagnostics is previewing a new point-of-care (POC) connectivity solution for its range of HbA1c analyzers at Medica 2016 in Düsseldorf from 14–17^th November.

Glycated Serum Protein LiquiColor test verified for Siemens Vista chemistry analyzer

EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor^® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer

Separation Technology moves its production and operations facility to Boerne, Texas

EKF Diagnostics, the global in-vitro diagnostics company, announces that Separation Technology, Inc., a subsidiary of EKF, has moved its manufacturing and operations from Sanford, Florida to Boerne, Texas.

EKF Diagnostics' Quo-Test HbA1c analyzer achieves class leading level of performance

EKF Diagnostics, the global in-vitro diagnostics company, announces the release of a significant critical evaluation of the Quo-Test analyzer carried out by the European Reference Laboratory for Gylcohemoglobin.

EKF Diagnostics has Point-of-Care at its heart

EKF Diagnostics, the global in vitro diagnostics company, is looking forward to an exciting second half of 2016 as it relaunches the HemoPoint® H2 hemoglobin analyzer in the USA under the Stanbio brand.